A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain
NCT ID: NCT03081806
Last Updated: 2024-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
399 participants
INTERVENTIONAL
2021-09-24
2024-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis
NCT02067611
Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis
NCT03691818
Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis
NCT05324163
Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain
NCT07226258
Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain
NCT05470608
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The WOMAC version 3.1 using the NRS will be used for the primary and secondary efficacy endpoints. Safety assessments will include assessment of AEs, vital signs (blood pressure, respiratory rate, pulse rate, and oral temperature), clinical laboratory tests, physical examination, skin irritation, and electrocardiograms (ECGs).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
High dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
X0002
Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
Group B
Low dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
X0002
Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
X0002
Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. An understanding, ability, and willingness to fully comply with study procedures and restrictions.
3. Subject must be a male or female between 35 and 85 years of age, inclusive.
4. Female subjects must either not be of childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile \[bilateral tubal ligation, bilateral oophorectomy, or hysterectomy\]) or be willing to Practice at least 1 of the following medically acceptable methods of birth control.
5. Subject must have a body mass index (BMI) between 18.5 and 45 kg/m2, inclusive.
6. Must have a history of clinically symptomatic OA of the knee for ≥6 months.
7. Must meet the American College of Rheumatology clinical classification criteria for knee OA. These criteria include the presence of knee pain in addition to at least 3 of the following 6 items:
* age of ≥50 years
* stiffness lasting \<30 minutes
* crepitus on knee motion
* Bony Tenderness
* Bony Enlargement
* No palpable warmth
8. A subject must have a Kellgren Lawrence Grade of 2,3 or 4 as determined by a central radiologist at the first screening visit. .
9. Subject must have had knee pain while standing, walking, and/or in motion for at least 14 days during the month prior to Screening.
10. Subject must have a knee pain score ≥4 and \<9 on 0-10 pain intensity NRS (without analgesic medication) on at least 7 of the 10 days prior to randomization.
11. Subject must be willing to discontinue any NSAIDs or other analgesic (eg, aspirin, acetaminophen) or potentially confounding concomitant treatments (eg, physiotherapy, acupuncture) starting on the first screening visit until completing participation in the study. (The use of ≤325 mg acetylsalicylic acid per day as cardiac prophylaxis is permitted.) The subject will be allowed to take rescue medication (acetaminophen) for pain during the study except during the 24 hours prior to the Second Screening Visit, Baseline (Day1), Week 2, Week 4, Week 8, Week 12, Week 22, Week 32, Week 42, and Week 52/EOS.
12. Subject must be willing to discontinue applying any topical preparations containing Vitamin A acids (including all trans retinoic acid (tretinoin), 13 cis retinoic acid \[isotretinoin\], 9 cis retinoic acid \[alitretinoin\], vitamin A \[retinol\], retinal, and their derivatives) to the lower limbs starting on the first screening visit until completing participation in the study. (Topical preparations containing Vitamin A acids or retinol may be applied to areas of the skin above the waist, but should not be applied to areas of the skin exposed to study medication.)
13. Subject must be willing to avoid unaccustomed physical activity (eg, starting a new weight lifting routine) for the duration of the study starting on the first screening visit.
14. With the exception of OA of the knee subjects with medical history must be stable as determined by the investigator.
Exclusion Criteria
2. Has a history of or is currently in litigation regarding joint injuries.
3. Has secondary OA of the target knee or OA of lower limb joints other than the knee that, in the investigator's opinion, could interfere with pain and functional assessments related to the target knee.
4. Has a history of total or partial knee replacement, arthroplasty, or other knee surgery on the target knee.
5. In the investigator's opinion, has had significant injury involving the target knee within the 6 months before Screening.
6. Has skin lesions or wounds on or near the target knee at Screening or at Baseline (Day 1) that, in the investigator's opinion, would affect absorption of the medication.
7. Has used opiates (including tramadol or tapentadol) or systemic corticosteroids within 30 days before Screening or requires treatment with chronic opiates or systemic corticosteroids.
8. Subjects with a placebo response exceeding 25% improvement in the average Western Ontario and McMaster Osteoarthritis Index \[WOMAC\] pain subscale score from Screening Visit to Day 1 will be excluded.
9. Has used gabapentin, pregabalin, antiepileptics, or specific antidepressants (i.e., tricyclics, serotonin norepinephrine reuptake inhibitors, or selective serotonin reuptake inhibitors) to treat pain in the 14 days before Screening. Other uses not related to the pain treatment may be permitted at the medical monitor's discretion provided they have been at a stable dose for at least 90 days.
10. Has had intra articular (IA) injections of corticosteroids, hyaluronic acid, or viscosupplements (e.g., Synvisc®) to the target knee within the 12 weeks before Screening
11. Has had IA or intravenous (IV) stem cell therapy in the 6 months prior to Screening
12. Is receiving or is planning to receive concomitant nonpharmacologic treatments (e.g., physiotherapy, acupuncture) that in the investigator's opinion could confound efficacy assessments within 14 days of Day 1.
13. Has a history of significant hypersensitivity, intolerance, or allergy to ibuprofen or any other NSAIDs, aspirin, or acetaminophen.
14. Has had an active gastrointestinal (GI) ulceration in the 6 months prior to Screening or a history of GI bleeding within 5 years of Screening.
15. Has used an anticoagulant or antiplatelet agent (except aspirin up to 325 mg/day for cardiac prophylaxis) in the 30 days prior to Screening.
16. Has a documented history of chronic inflammatory disease (e.g., rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, gouty arthritis) OR chronic pain condition (e.g., fibromyalgia), OR has other conditions that may affect the target joint for the functional and pain assessments (e.g., osteonecrosis, chondrocalcinosis).
17. Has uncontrolled depression or other uncontrolled psychiatric disorder (subjects with controlled depression or other psychiatric disorder, if using medication, must be on a stable dose of a medication other than an epileptic, tricyclic, serotonin norepinephrine reuptake inhibitor, or selective reuptake inhibitor for ≥12 weeks prior to Screening to participate in the study).
18. Has asthma requiring treatment with systemic corticosteroids in the last year prior to Screening. Asthmatic subjects using inhaled corticosteroids are eligible.
19. Has uncontrolled hypertension defined as systolic blood pressure \>170 mmHg and diastolic blood pressure \>90 mmHg at the Screening or Baseline Visit (may be repeated after 5 minutes rest to verify).
20. Is receiving systemic chemotherapy, has an active malignancy, lymphoproliferative disorder, or blood dyscrasia of any type, or has been diagnosed with cancer within 5 years before Screening. Subjects with completely excised squamous or basal cell carcinoma of the skin will be allowed.
21. Has any clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, hepatic, or renal disease, or any other condition that, in the Investigator's opinion, could confound the study results, compromise the subject's welfare, interfere with the ability to communicate with the study staff, or otherwise contraindicate study participation.
22. Has any of the following conditions at Screening:
* Acute hepatitis
* Cirrhosis
* Stage 4 or 5 end-stage renal disease
23. Subject has any other clinically significant laboratory finding at Screening that in the investigator's opinion contraindicates study participation.
24. Has clinically significant abnormality at Screening or Baseline (Day 1) on 12-lead ECG, including a QT interval calculated using Fridericia's correction (QTcF) interval \>500 milliseconds (msec) or evidence of cardiac ischemia (i.e., Evident q waves: t wave inversion).
25. Is pregnant, planning to become pregnant during the study, or lactating. Has a positive serum and urine pregnancy test at Screening Visit, or a positive urine pregnancy test at Baseline (Day 1).
26. Has a positive urine drug screen for a nonprescribed drug prohibited by the protocol at Screening.
27. Has known alcohol or other substance abuse in the investigator's opinion.
28. Has participated in a previous clinical study with X0002.
29. Has participated in any other clinical trial within the past 30 days or within 5 half-lives of the study drug prior to Screening, whichever is longer.
30. Is a participating investigator, sub-investigator, study coordinator, or employee of a participating investigator, or is an immediate family member of the aforementioned.
31. Has any factor that, in the investigator's opinion, would jeopardize the evaluation or safety or be associated with poor adherence to the protocol.
32. Is without access to telephone and/or ability to gain technology access.
35 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Techfields Pharma Co. Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chongxi Yu, PhD
Role: STUDY_CHAIR
Techfields Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Research Center
Phoenix, Arizona, United States
Yuma Clinical Trials
Yuma, Arizona, United States
Orange County Research Institute
Anaheim, California, United States
Biosolutions Clinical Research Center
La Mesa, California, United States
Velocity Clinical Research
North Hollywood, California, United States
University Clinical Research-Deland
DeLand, Florida, United States
Reliable Clinical Research
Hialeah, Florida, United States
Health Awareness Inc.
Jupiter, Florida, United States
Ascension Research
Pinellas Park, Florida, United States
Conquest Research
Winter Park, Florida, United States
Horizon Clinical Research
Newnan, Georgia, United States
Pinnacle Trials Inc
Stockbridge, Georgia, United States
Chicago Clinical Research Institute Inc
Chicago, Illinois, United States
Northwestern University
Chicago, Illinois, United States
Healthcare Research Network
Flossmoor, Illinois, United States
Affinity Health Corp
Oak Brook, Illinois, United States
DelRicht Research
New Orleans, Louisiana, United States
DelRicht Research
Prairieville, Louisiana, United States
DelRicht Research - Gulfport
Gulfport, Mississippi, United States
Healthcare Research Network, LLC
Hazelwood, Missouri, United States
AMR Kansas City
Kansas City, Missouri, United States
Sundance Clinical Research, LLC
St Louis, Missouri, United States
AMR: Las Vegas
Las Vegas, Nevada, United States
Upstate Clinical Research Associates LLC
Williamsville, New York, United States
Aventiv Research, Inc - Brice Road Location
Columbus, Ohio, United States
DelRicht Research
Tulsa, Oklahoma, United States
Altoona Center For Clinical Research
Duncansville, Pennsylvania, United States
Tekton Research
Austin, Texas, United States
Clinical Investigations of Texas
Plano, Texas, United States
Quality Research Inc.
San Antonio, Texas, United States
Wasatch Clinical Research LLC
Salt Lake City, Utah, United States
Charlottesville Medical Research, LLC
Charlottesville, Virginia, United States
Spectrum Medical, Inc
Danville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TF-X0002-31
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.